Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous (SC) Doses of rAvPAL-PEG in Subjects With PKU
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Pegvaliase (Primary)
- Indications Phenylketonuria
- Focus Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 24 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 08 Apr 2015 Planned End Date changed from 1 Jul 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
- 08 Apr 2015 Planned primary completion date changed from 1 Mar 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.